Olga Zajac-Spychala

Dr. Olga Zajac-Spychala

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JWJadwiga Weclawek-Tompol
Jadwiga Weclawek-Tompol
ZZZuzanna Zakrzewska
Zuzanna Zakrzewska
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
FPFilip Pierlejewski
Filip Pierlejewski
EBEwa Bien
Ewa Bien
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, children present milder symptoms, with most having an asymptomatic course. We hypothesized that COVID-19 infection has a negative impact on the continuation of chemotherapy and increases nonrelapse mortality. Material and methods: This study was performed to assess the course of SARS-CoV-2 among children with hematological or oncological malignancies and its impact on cancer therapy. Records of SARS-CoV-2 infection in 155 children with malignancies from 14 Polish centers for pediatric hematology and oncology were collected and analyzed. Results: SARS-CoV-2 replication was observed in 155 patients. Forty-nine patients were symptomatic, with the following being the most common manifestations: fever (31 patients), gastrointestinal symptoms (10), coryza (13), cough (13) and headache (8). In children who were retested, the median time of a positive PCR result was 16 days (range 1–70 days), but 12.7% of patients were positive beyond day + 20. The length of viral PCR positivity correlated with the absolute neutrophil count at diagnosis. Seventy-six patients did not undergo further SARS-CoV-2 testing and were considered convalescents after completion of isolation. Antibiotic therapy was administered in 15 children, remdesivir in 6, convalescent plasma in 4, oxygen therapy in 3 (1—mechanical ventilation), steroids in 2, intravenous immunoglobulins in 2, and heparin in 4. Eighty patients were treated with chemotherapy within 30 days after SARS-CoV-2 infection diagnosis or were diagnosed with SARS-CoV-2 infection during 30 days of chemotherapy administration. Respiratory symptoms associated with COVID-19 and associated with oxygen therapy were present in 4 patients in the study population, and four deaths were recorded (2 due to COVID-19 and 2 due to progressive malignancy). The probability of 100-day overall survival was 97.3% (95% CI 92.9–99%). Delay in the next chemotherapy cycle occurred in 91 of 156 cases, with a median of 14 days (range 2–105 days). Conclusions: For the majority of pediatric cancer patients, SARS-CoV-2 infection does not result in a severe, life-threatening course. Our data show that interruptions in therapy are common and can result in suboptimal therapy.

10 January 2017 in Neuroradiology
Verified
Journal Article
Open access
PDF file
OZOlga Zajac-Spychala
Olga Zajac-Spychala
MPMikołaj A. Pawlak
Mikołaj A. Pawlak
KKKatarzyna Karmelita-Katulska
Katarzyna Karmelita-Katulska
JPJakub Pilarczyk
Jakub Pilarczyk
KDKatarzyna Derwich
Katarzyna Derwich
JWJacek Wachowiak
Jacek Wachowiak
The aim of this study was to assess the long-term side effects of central nervous system prophylaxis (high-dose chemotherapy alone vs chemotherapy and CNS radiotherapy) according to the ALL IC-BFM 2002.

5 July 2018 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMałgorzata Salamonowicz-Bodzioch
Małgorzata Salamonowicz-Bodzioch
TOTomasz Ociepa
Tomasz Ociepa
JFJ. Frączkiewicz
J. Frączkiewicz
ASAnna Szmydki-Baran
Anna Szmydki-Baran
MMM. Matysiak
M. Matysiak
JSJan Styczyński
Jan Styczyński
Clostridium difficile infection (CDI) is one of the most common causes of nosocomial infectious diarrhea in children during anticancer therapy or undergoing hematopoietic stem cell transplantation (HSCT) in Europe. Immunosuppression in these patients is a risk factor for CDI. Malignant diseases, age, acute graft-versus-host disease (aGVHD), HLA mismatch, or use of total body irradiation may play an important role in CDI course. The aim of this study was to evaluate the incidence, course, and outcome of CDI in children treated for malignancy or undergoing HSCT. Between 2012 and 2015, a total number of 1846 patients were treated for malignancy in Polish pediatric oncological centers (PHO group) and 342 underwent transplantation (HSCT group). In PHO group, episodes of CDI occurred in 210 patients (14%). The incidence of CDI was higher in patients with hematological malignancies in comparison to that with solid tumors. Patients with acute myeloblastic leukemia had shorter time to episode of CDI than those with acute lymphoblastic leukemia. Patients over 5 years and treated for acute leukemia had more severe clinical course of disease in PHO group. In HSCT group, CDI occurred in 29 (8%) patients. The incidence of CDI was higher in patients transplanted for acute leukemia. The recurrence rate was 14.7% in PHO and 20.7% in HSCT patients. CDI incidence was highest in patients with hematological malignancies. Most of patients experienced mild CDI. Age < 5 years and diagnosis other than acute leukemia were the positive prognostic factors influencing clinical CDI course.

23 September 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
OZOlga Zajac-Spychala
Olga Zajac-Spychala
JWJ. Wachowiak
J. Wachowiak
APA. Pieczonka
A. Pieczonka
KSK. Siewiera
K. Siewiera
JFJ. Frączkiewicz
J. Frączkiewicz
JSJ. Styczyński
J. Styczyński

1 October 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
KDKatarzyna Drabko
Katarzyna Drabko
ASAnna Szmydki-Baran
Anna Szmydki-Baran
AZAgnieszka Zaucha-Prażmo
Agnieszka Zaucha-Prażmo
MLMonika Lejman
Monika Lejman
JSJan Styczyński
Jan Styczyński

15 January 2021 in Microbial Drug Resistance
Verified
Journal Article
Closed access
OZOlga Zajac-Spychala
Olga Zajac-Spychala
JWJacek Wachowiak
Jacek Wachowiak
OGOlga Gryniewicz–Kwiatkowska
Olga Gryniewicz–Kwiatkowska
AGAneta Gietka
Aneta Gietka
BDBozenna Dembowska-Baginska
Bozenna Dembowska-Baginska
JSJan Styczynski
Jan Styczynski
Background: Infectious complications (IC) caused by bacterial strains often impede anticancer therapy. The study aimed to retrospectively analyze bacterial IC that could help predict the risk and optimize the empirical treatment for bacterial infections in pediatric cancer patients. Patients and Methods: Over a 72-month period, all-in 5,599 children with cancer: 2,441 patients with hematological malignancy (HM including acute leukemias, Hodgkin and non-Hodgkin lymphomas [NHLs], and Langerhans cell histiocytosis) and 3,158 with solid tumors (STs including central nervous system tumors, neuroblastoma, Wilms' tumor, soft tissue sarcoma, germ cell tumors, Ewing sarcoma, osteosarcoma, hepatoblastoma, and others) were enrolled into the study. Episodes of bacterial infectious complications (EBICs) confirmed by microbiological findings were reported by each hospital and analyzed centrally. Results: At least 1 EBIC was diagnosed in 2,155 (36.8%) children (1,281 [59.4%] with HM and 874 [40.6%] with ST; p < 0.001). All-in 4,860 EBICs were diagnosed including 62.2% episodes in children with HM and 37.8% in children with ST ( p < 0.001). Having analyzed the source of infections, blood stream infections predominated, apart from NHL patients in whom the most common type was gut infections. The profile of bacteria strains was different in HM and ST groups ( p < 0.001). However, in both groups the most common Gram-negative pathogen was Enterobacteriaceae, with the rate being higher in the HM group. Among Gram-negative strains low susceptibility to ceftazidime, whereas among Enterococcus spp. low susceptibility to vancomycin was noticed. The rate of multidrug-resistant (MDR) pathogens was high, especially for Gram negatives (47.7% vs. 23.9%; p < 0.001). The survival after infections was comparable for HM and ST patients ( p = 0.215). Conclusions: The risk of bacterial IC in HM patients was higher than in the ST group. The high rate of MDR strains was detected in pediatric cancer patients, especially in those with HM.